NAD precursors, evidence snapshot: NMN, NR, niacin, and what human trials measured

Key takeaways

• NMN and NR are NAD+ precursors. Both reliably raise whole-blood NAD+ surrogate markers in human pharmacokinetic trials at typical supplement doses (250-1000 mg daily).
• FDA position is that NMN is excluded from the dietary-supplement definition because it has been authorized for investigation as a new drug. NMN is sold as a supplement despite the contested status.
• Nicotinamide riboside chloride (Niagen / Tru Niagen) has clearer NDI / GRAS status and is the regulatorily safer option in the US.
• Almost all published NMN and NR trials use surrogate endpoints (NAD+ levels, insulin sensitivity, blood pressure). No published trial uses hard outcome endpoints (mortality, cardiovascular events, incident dementia) as a primary endpoint.
• Adverse-event profiles at studied doses are mild across both compounds; long-term safety beyond ~12 months of continuous dosing is not characterized.

The NAD biology, briefly

Nicotinamide adenine dinucleotide (NAD+) is a redox cofactor central to oxidative phosphorylation, and it is also the substrate for NAD-consuming enzymes including the sirtuins, the PARP family, and the CD38 cell-surface ectoenzyme. Tissue NAD levels decline modestly with age in some animal and human cross-sectional data; CD38 expression rises with age, providing one mechanistic explanation for the decline. The combination drove the modern interest in NAD precursors as a way to support tissue NAD levels .

Five precursors feed into the NAD salvage and de novo pathways: tryptophan (de novo), nicotinic acid (NA / niacin), nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). NAM and NA have decades of human clinical use at gram doses (pellagra prevention, lipid management). NR and NMN are the newer precursors that anchor the modern longevity-supplement conversation.

NMN vs NR: the biosynthetic difference

Once inside the cell, both NR and NMN funnel into the NAD salvage pathway. The pathways diverge at the cell membrane. Oral NR is taken up via nucleoside transporters and converted to NMN by nicotinamide riboside kinase (NRK1/NRK2), and NMN is then converted to NAD+ by NMN adenylyltransferase (NMNAT). Oral NMN is debated: NMN can be dephosphorylated to NR at the brush border or transported intact via the SLC12A8 transporter that one influential preclinical study identified, although that transporter's role is contested in the published literature .

Practical implication: oral NMN may largely act through the same intracellular salvage as oral NR. Whether NMN offers any meaningful pharmacokinetic or pharmacodynamic advantage over NR in humans is not settled in the published trial record.

NR (nicotinamide riboside): the human trial record

Trammell and colleagues (2016) published the first oral NR pharmacokinetic trial in 12 healthy adults, demonstrating dose-dependent increases in whole-blood NAD+ at 100 mg, 300 mg, and 1000 mg single doses . Conze and colleagues (2019) extended this with a 8-week safety and tolerability study at up to 1000 mg/day, reporting elevated whole-blood NAD+ throughout dosing and a clean adverse-event profile .

Martens and colleagues (2018) ran a 6-week randomized crossover in middle-aged and older adults at 1000 mg/day; whole-blood NAD+ increased approximately 60 percent. The trial showed a small reduction in systolic blood pressure and aortic stiffness in subjects with elevated baseline values; the broader cardiovascular and longevity endpoints were not powered for outcome conclusions .

Subsequent trials have explored NR in Parkinson's disease (NADPARK reported NR raised brain NAD+ on MRS imaging and produced small motor improvements), in older adults (mitochondrial function endpoints), and in chronic kidney disease (small efficacy and tolerability signals). The pattern is consistent: NR reliably raises whole-blood and tissue NAD+ surrogate markers, with smaller and more variable effects on functional or outcome endpoints .

NMN: the human trial record

Irie and colleagues (2020) published the first single-dose NMN PK study in 10 healthy Japanese men, showing tolerability up to 500 mg and increased downstream NAD-metabolite markers . Yoshino and colleagues (2021) ran a 10-week randomized trial of NMN 250 mg/day in 25 postmenopausal women with prediabetes; insulin sensitivity (hyperinsulinemic-euglycemic clamp) improved in the NMN arm without large changes in body composition or blood pressure .

Liao and colleagues (2021) reported a 6-week trial of NMN 300 mg/day in middle-aged amateur runners with improvements in aerobic capacity (VO2 metrics) over placebo; the result was statistically significant but modest in absolute terms . Yamane and colleagues (2023) published a 12-week dose-finding trial in older adults at 250-1250 mg/day, reporting linear increases in serum NAD+ markers and a tolerable safety profile .

All of these trials are surrogate-endpoint, short-duration, and small. None establishes NMN as a longevity or healthspan therapy.

The FDA NDI dispute over NMN

In late 2022, the FDA notified at least one NMN supplement marketer that the agency considered NMN excluded from the dietary-supplement definition under section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act, on the basis that NMN had been authorized for investigation as a new drug and had been the subject of substantial clinical investigation made public. The FDA position effectively says NMN cannot be a lawful dietary ingredient in the United States .

Despite the FDA position, NMN continues to be sold widely as a dietary supplement. The legal dispute is unresolved and is the subject of ongoing industry advocacy and FDA enforcement discretion. Buyers in the US should understand that the regulatory status of NMN as a dietary supplement is contested.

NR NDI status (and the GRAS pathway)

Nicotinamide riboside chloride (the form sold as Niagen / Tru Niagen) reached GRAS no-questions status in 2016 (FDA GRAS Notice GRN 000635) and has been recognized through the New Dietary Ingredient notification process, with NIAGEN NDI notifications acknowledged in 2015 and again in 2018 . NR therefore has a clearer dietary-supplement status than NMN. ChromaDex and partners have published the underlying safety packages and pharmacokinetic data that support that status .

Practical implication: NR currently has the cleaner regulatory pathway in the US for dietary supplement marketing. The trial-evidence base for NR and NMN is broadly comparable in size and quality, but the regulatory clarity differs.

Surrogate markers vs outcome endpoints

Almost every NMN and NR trial published as of 2026 uses surrogate endpoints: whole-blood or tissue NAD+ levels, NAD-metabolite ratios (NAAD/NAD+, MeNAM), grip strength, walking speed, insulin sensitivity, blood pressure, aerobic capacity. None has used hard outcome endpoints (mortality, cardiovascular events, incident dementia, incident type 2 diabetes) as a primary endpoint over a multi-year follow-up.

This is not a criticism of the trials. It reflects the cost and timeline of outcome trials versus surrogate-endpoint pilots. It is, however, the honest reason that the longevity / healthspan claims attached to NAD precursors in marketing materials run far ahead of the evidence in the peer-reviewed record.

Safety and side effects

Adverse-event profiles in NR trials at doses up to 1000 mg/day have been mild and broadly indistinguishable from placebo across multiple trials . NMN trials at 250-1250 mg/day report similar tolerability. Mild GI symptoms (nausea, diarrhea, headache) appear in some subjects across both compounds. Pruritus and flushing of the niacin type are not characteristic of NR or NMN at supplement doses (unlike NA / niacin at gram doses).

Long-term safety beyond ~12 months of continuous dosing is not characterized in published trials. Theoretical concerns about NAD-metabolite accumulation, methyl-group depletion (since NAM clearance proceeds via methylation to MeNAM and 1-methylnicotinamide), and cancer-cell metabolism support remain academic discussions rather than reported clinical signals.

What the trials do not answer

• Whether sustained whole-blood NAD+ elevation translates into reduced age-related disease incidence or mortality.
• Whether NMN and NR are clinically distinguishable in outcomes that matter, despite different biosynthetic routes.
• Whether tissue-level (not whole-blood) NAD+ is meaningfully changed in skeletal muscle, liver, brain at the doses studied.
• Whether timing (morning vs evening), pulsatile vs continuous dosing, or combination with other interventions (sirtuin activators, metformin, exercise) affects outcomes.
• Whether NAD precursors interact with cancer-cell metabolism in ways that matter for safety in any specific population.

Regulatory and doping posture

FDA: NR has acknowledged NDI / GRAS status ; NMN has a contested status under FDA's drug-exclusion position . Neither compound is FDA-approved as a drug. ODS-NIH publishes consumer-facing summaries of niacin / NAD precursor evidence and risk . WADA: neither NR nor NMN is on the WADA prohibited list as of the current annual list.

Cochrane has not published a definitive systematic review of NR or NMN clinical outcomes; the published systematic reviews are non-Cochrane and tend to conclude that surrogate-marker evidence is consistent but outcome evidence is absent.

Editorial summary

NMN and NR reliably raise NAD+ surrogate markers in humans. The marketing claims about longevity and healthspan run ahead of the trial record, which is short-duration, small-population, and surrogate-endpoint. NR has a clearer regulatory pathway in the US than NMN. Long-term safety is tolerable in published trials, but multi-year exposure data are limited.